A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH2929 Injection in Patients With Acute Exacerbations of Generalized Pustular Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.
• Age ≥ 18 or ≤75 years old at screening, regardless of gender;
• Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as （generalized pustular psoriasis(GPP);
• Compliant with GPP acute onset;
• Able to read and understand, and willing to sign the informed consent form;
• Willing and compliant with study visits and related procedures;
• Female subjects of childbearing age should agree that contraceptive measures must be used during the study and for 6 months after the end of the study;